Bill and Melinda Gates Foundation. Online document at: www.gatesfoundation.org Accessed October21, 2016.
2.
Zilberman-SchapiraG, ZmoraN, ItavS, et al.The gut microbiome in human immunodeficiency virus infection. BMC Med, 2016; 14:8–3.
3.
DillonSM, FrankDN, WilsonCC. The gut microbiome and HIV-1 pathogenesis: A two way street. AIDS, 2016; 30:2737–2751.
4.
LingZ, JinC, XieT, et al.Alterations in the fecal microbiota of patients with HIV-1 infection: An observational study in a Chinese population. Sci Rep, 2016; 6:3067–3.
5.
DubourgG, LagierJC, HueS, et al.Gut microbiota associated with HIV infection is significantly enriched in bacteria tolerant to oxygen. BMJ Open Gastroenterol, 2016; 3:e00008–0.
6.
GailH, TarrynB, OluwaseyiA, et al.An ethnobotanical survey of medicinal plants used by traditional health practitioners to manage HIV and its related opportunistic infections in Mpoza, Eastern Cape Province, South Africa. J Ethnopharmacol, 2015; 171:109–115.
7.
AudetC, BlevinsM, RosenbergC, et al.Symptomatic HIV-positive persons in rural Mozambique who first consult a traditional healer have delays in HIV testing: A cross-sectional study. J Acquir Immune Defic Syndr, 2014; 66:e80–e86.
8.
DavidsD, BlouwsT, AboyadeO, et al.Traditional health practitioners' perceptions, herbal treatment and management of HIV and related opportunistic infections. J Ethnobiol Ethnomed, 2014; 10:7–7.
9.
AfolayanA, OtunolaG. Ultrastructure and elemental analysis of Hypoxis hemerocallidea: A multipurpose medicinal plant. Afr J Tradit Complement Altern Med, 2014; 11:39–43.
10.
JohnsonQ, SyceJ, NellH, et al.A randomized, double-blind, placebo-controlled trial of Lessertia frutescens in healthy adults. PLoS Clin Trials, 2007; 2:e1–6.
11.
HelferM, KoppensteinerH, SchneiderM, et al.The root extract of the medicinal plant Pelargonium sidoides is a potent HIV-1 attachment inhibitor. PLoS One, 2014; 9:e8748–7.
12.
KaufmanM, IoergerM, HarmanJ, ModarresN. Nature, extent and implications of belief in Kikombe cha babu and other herbal HIV cures in Tanzania. AIDS Care, 2014; 26:1541–1545.
13.
AyubaG, JensenG, BensonK, et al.Clinical efficacy of a West African sorghum bicolor-based traditional herbal preparation Jobelyn shows increased hemoglobin and CD4+ T-lymphocyte counts in HIV-positive patients. J Altern Complement Med, 2014; 20:53–56.
14.
OnifadeA, JewellA, AdedejiW. Nigella sativa concoction induced sustained seroreversion in HIV patient. Afr J Tradit Complement Altern Med, 2013; 10:332–335.
15.
MugishaM, AsiimweS, NamutebiA, et al.Ethnobotanical study of indigenous knowledge on medicinal and nutritious plants used to manage opportunistic infections associated with HIV/AIDS in western Uganda. J Ethnopharmacol, 2014; 155:194–202.
16.
OuattaraB, KraAM, CoulibalyA, Guede-GuinaF. Efficiency of ethanol of Thonningia sanguinea against Cryptococcus neoformans. Sante, 2007; 17:219–222.
17.
LiuZB, YangJP, XuLR. Effectiveness and safety of Traditional Chinese Medicine in treating acquired immune deficiency syndrome: 2004–2014. Infect Dis Poverty, 2015; 4:5–9.
18.
DengX, JiangM, ZhaoX, LiangJ. Efficacy and safety of Traditional Chinese Medicine for the treatment of acquired immunodeficiency syndrome: A systematic review. J Tradit Chin Med, 2014; 34:1–9.
19.
WangJ, LiangB, ZhangX, et al.An 84-month observational study of the changes in CD4 T-lymphocyte cell count of 110 HIV/AIDS patients treated with Traditional Chinese Medicine. Front Med, 2014; 8:362–367.
20.
ZouW, LiuY, WangJ, et al.Traditional Chinese herbal medicines for treating HIV infections and AIDS. Evid Based Complement Alternat Med, 2012; 2012:95075–7.
21.
JiangF, ZhangR, GuZ, et al.Fuzhengpaidu granule regulates immune activation molecules CD38 and human leukocyte antigen-D related on CD4+ and CD8+ T cells in patients with acquired immunodeficiency syndrome/human immunodeficiency virus. J Tradit Chin Med, 2013; 33:439–443.
22.
KusumM, KlinbuayaemV, BunjobM, SangkitpornS. Preliminary efficacy and safety of oral suspension SH, combination of five Chinese medicinal herbs, in people living with HIV/AIDS; the Phase I/II study. J Med Assoc Thai, 2004; 87:1065–1070.
23.
WangYS, WenZQ, LiBT, et al.Ethnobotany, phytochemistry, and pharmacology of the genus Litsea: An update. J Ethnopharmacol, 2016; 181:66–107.
24.
LvM, XuP, TianY, et al.Medicinal uses, phytochemistry and pharmacology of the genus Dictamnus (Rutaceae). J Ethnopharmacol, 2015; 171:247–263.
25.
XuL, GrandiN, Del VecchioC, et al.From the Traditional Chinese Medicine plant Schisandra chinensis new scaffolds effective on HIV-1 reverse transcriptase resistant to non-nucleoside inhibitors. J Microbiol, 2015; 53:288–293.
26.
LiangJ, ChenJ, TanZ, et al.Extracts of medicinal herb Sanguisorba officinalis inhibit the entry of human immunodeficiency virus type one. HHS Public Access PMC, 2013; 21:S52–S58.
27.
MerensteinD, YangY, SchneiderM, et al.Association of complementary and alternative medicine use with highly active antiretroviral therapy initiation. Altern Ther Health Med, 2008; 14:18–22.
28.
StandishL, CalabreseC, ReevesC, et al.A scientific plan for the evaluation of alternative medicine in the treatment of HIV/AIDS. 1997; 3:58–67.
29.
TargE. CAM and HIV/AIDS: The importance of complementarity. Altern Ther Health Med, 2000; 6.
30.
Gore-FeltonC, VosvickM, PowerR, et al.Alternative therapies: A common practice among men and women living with HIV. J Assoc Nurses AIDS Care, 2003; 14:17–27.
31.
de VisserR, EzzyD, BartosM. Alternative or complementary? Nonallopathic therapies for HIV/AIDS. Altern Ther Health Med, 2000; 6:44–52.
32.
FaragonJ, PurdyB, PelieroP. An assessment of herbs and utilization of pharmacy services in HIV clinics. J Herb Pharm, 2004; 37.
33.
O'ConnorB. Vernacular health care responses to HIV and AIDS. Altern Ther Health Med, 1995; 1.
34.
HarrisGE, DupuisL, MugfordGJ, et al.Patterns and correlates of cannabis use among individuals with HIV/AIDS in Maritime Canada. Can J Infect Dis Med Microbiol, 2014; 25:e1–7.
35.
MaorY, YuJ, KuzontkoskiP, et al.Cannabidiol inhibits growth and induces programmed cell death in Kaposi sarcoma-associated herpesvirus-infected endothelium. Genes Cancer, 2012; 3:512–520.
36.
WhitingPF, WolffRF, DeshpandeS, et al.Cannabinoids for medical use: A systematic review and meta-analysis. JAMA, 2015; 313:2456–2473.
37.
MerlinJS, BullsHW, VucovichLA, et al.Pharmacologic and non-pharmacologic treatments for chronic pain in individuals with HIV: A systematic review. AIDS Care, 2016; 28:1506–1515.
38.
ThamesAD, MahmoodZ, BurggrenAC, et al.Combined effects of HIV and marijuana use on neurocognitive functioning and immune status. AIDS Care, 2016; 28:628–632.
39.
MilloyMJ, MarshallB, KerrT, et al.High-intensity cannabis use associated with lower plasma HIV-1 RNA viral load among recently infected people who use injection drugs. Drug Alcohol Rev, 2015; 34:135–140.
40.
ChandraL, KumarV, TorbenW, et al.Chronic administration of THC induces intestinal anti-inflammatory microRNA expression during acute simian immunodeficiency virus infection of rhesus macaques. J Virol, 2015; 89:1168–1181.
41.
SchoutenJ, SuT, WitFW, et al.Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy. AIDS, 2016; 30:1027–1038.
42.
SlawsonG, MilloyMJ, BalneavesL, et al.High-intensity cannabis use and adherence to antitretroviral therapy among people who use illicit drugs in a Canadian setting. AIDS Behav, 2015; 19:120–127.
43.
GrossIM, HosekS, RichardsMH, FernandezMI. Predictors and profiles of antiretroviral therapy adherence among African American adolescents and young adult males living with HIV. AIDS Patient Care STDS, 2016; 30:324–338.
44.
McPartlandJM. Medical marijuana and its use by the immunocompromised. Alt Ther, 1997; 3:39–45.
45.
BirtD, WidriechnerM, HammerK, et al.Hypericum in infection: Identification of anti-viral and anti-inflammatory constituents. Pharm Biol, 2009; 47:774–782.
46.
TaherMM, LammeringGM, HersheyCM, ValerieKC. Mood-enhancing antidepressant St. John's Wort inhibits the activation of human immunodeficiency virus gene expression by ultraviolet light. IUBMB Life, 2002; 54:357–364.
47.
MauryW, PriceJ, BrindleyM, et al.Identification of light-independent inhibition of human immunodeficiency virus-1 infection through bioguided fractionation of Hypericum perforatum. Virol J, 2009; 6:10–1.
48.
PereraT, BernaA, ScottK, et al.Proteins related to St. John's Wort p27SJ, a suppressor of HIV-1 expression, are ubiquitous in plants. Phytochemistry, 2008; 69:865–872.
49.
DarbinianN, KhaliliK, AminiS. Neuroprotective activity of pDING in response to HIV-1 Tat. J Cell Physiol, 2014; 229:153–161.
50.
EspositoF, SannaC, Del VecchioC, et al.Hypericum hircinum L. components as new single-molecule inhibitors of both HIV-1 reverse transcriptase-associated DNA polymerase and ribonuclease H activities. Pathog Dis, 2013; 68:116–124.
51.
TanakaN, OkasakaM, IshimaruY, et al.Biyouyanagin A, an anti-HIV agent from Hypericum chinense L. var. salicifolium. Org Lett, 2005; 7:2997–2999.
52.
FasinuPS, GurleyBJ, WalkerLA. Clinically relevant pharmacokinetic herb–drug interactions in antiretroviral therapy. Curr Drug Metab, 2015; 17:52–64.
53.
StolbachA, PazianaK, HeverlingH, PhamP. A review of the toxicity of HIV medications II: Interactions with drugs and complementary and alternative medicine products. J Med Toxicol, 2015; 11:326–341.
54.
AbdullahTH, KirkpatrickDV, CarterJ. Enhancement of natural killer cell activity in AIDS with garlic. Dtsch Zsohr Onkol, 1989; 21:52–53.
55.
LiuC, WangC, RobisonE, et al.Short-term garlic supplementation and highly active antiretroviral treatment adherence, CD4+ cell counts, and human immunodeficiency virus viral load. Altern Ther Health Med, 2012; 18:18–22.
56.
RaoPSS, MiddeNM, MillerDD, et al.Diallyl sulfide: Potential use in novel therapeutic interventions in alcohol, drugs, and disease mediated cellular toxicity by targeting cytochrome P450 2E1. Curr Drug Metab, 2015; 16:486–503.
57.
KaurP, SinghR. In vivo interactive effect of garlic oil and vitamin E against stavudine induced genotoxicity in Mus musculus. Indian J Exp Biol, 2007; 45:807–811.
58.
ColpittsCC, SchangLM. A small molecule inhibits virion attachment to heparan sulfate- or sialic acid-containing glycans. J Virol, 2014; 88:7806–7817.
59.
CastellanoLM, HammondRM, HolmesVM, et al.Epigallocatechin-3-gallate rapidly remodels PAP85-120, SEM1(45-107), and SEM2(49-107) seminal amyloid fibrils. Biol Open, 2015; 4:1206–1212.
60.
NathS, BachaniM, HarshavardhanaD, SteinerJP. Catechins protect neurons against mitochondrial toxins and HIV proteins via activation of the BDNF pathway. J Neurovirol, 2012; 18:445–455.
61.
KurapatiKR, SamikkannuT, AtluriVS, et al.Beta-amyloid1-42, HIV-1Ba-L (clade B) infection and drugs of abuse induced degeneration in human neuronal cells and protective effects of ashwagandha (Withania somnifera) and its constituent Withanolide A. PLoS One, 2014; 9:e11281–8.
62.
KurapatiKR, AtluriVS, SamikkannuT, NairM. Ashwagandha (Withania somnifera) reverses beta-amyloid1-42 induced toxicity in human neuronal cells: Implications in HIV-associated neurocognitive disorders (HAND). PLoS One, 2013; 8:e7762–4.
63.
OhC, PriceJ, BrindleyM, et al.Inhibition of HIV-1 infection by aqueous extracts of Prunella vulgaris L. Virol J, 2011; 8:18–8.
64.
KreisW, KaplanMH, FreemanJ, et al.Inhibition of HIV replication by Hyssop officinalis extracts. Antiviral Res, 1990; 14:323–337.
65.
GollapudiS, SharmaHA, AggarwalS, et al.Isolation of a previously unidentified polysaccharide (MAR-10) from Hyssop officinalis that exhibits strong activity against human immunodeficiency virus type 1. Biochem Biosphys Res Commun, 1995; 210:145–151.
66.
SungH, KangSM, LeeMS, et al.Korean red ginseng slows depletion of CD4 T cells in human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol, 2005; 12:497–501.
67.
SungH, JungYS, ChoYK. Beneficial effects of a combination of Korean red ginseng and highly active antiretroviral therapy in human immunodeficiency virus type 1-infected patients. Clin Vaccine Immunol, 2009; 16:1127–1131.
68.
SeeDM, BroumandN, SahlL, TillesJG. In vitro effects of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients. Immunopharmacology, 1997; 35:229–235.
69.
JeongJJ, KimB, KimDH. Ginsenoside Rb1 eliminates HIV-1 (D3)-transduced cytoprotective human macrophages by inhibiting the AKT pathway. J Med Food, 2014; 17:849–854.
70.
CalderonMM, ChairezCL, GordonLA, et al.Influence of Panax ginseng on the steady state pharmacokinetic profile of lopinavir-ritonavir in healthy volunteers. Pharmacotherapy, 2014; 34:1151–1158.
71.
AndradeAS, HendrixC, ParsonsTL, et al.Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir. BMC Complement Altern Med, 2008; 8:5–0.
72.
LeeLS, WiseSD, ChanC, et al.Possible differential induction of Phase 2 enzyme and antioxidant pathways by American ginseng, Panax quinquefolius. J Clin Pharmacol, 2008; 48:599–609.
73.
BakshiRP, BrownTT, SimmonsA, et al.American ginseng (Panax quinquefolius) administration does not affect performance of the Roche COBAS Ampliprep/Taqman HIV-1 RNA assay. BMC Complement Altern Med, 2014; 14:42–7.
74.
WangHX, NgTB. Quinqueginsin, a novel protein with anti-human immunodeficiency virus, antifungal, ribonuclease and cell-free translation-inhibitory activities from American ginseng roots. Biochem Biophys Res Commun, 2000; 269:203–208.
75.
AkbarR, YamWK. Interaction of ganoderic acid on HIV related target: Molecular docking studies. Bioinformation, 2011; 7:413–417.
76.
WangHX, NgTB. A laccase from the medicinal mushroom Ganoderma lucidum. Appl Microbiol Biotechnol, 2006; 72:508–513.
77.
MayellM. Maitake extracts and their therapeutic potential—A review. Alt Med Rev, 2001; 6:48–60.
78.
MoltoJ, ValleM, MirandaC, et al.Herb–drug interactions between Echinacea purpurea and etravirine in HIV-infected patients. Antimicrob Agents Chemother, 2012; 56:5328–5331.
79.
KienleGS. The story behind mistletoe: A European remedy from anthroposophical medicine. Altern Ther Health Med, 1999; 5:34–36.
80.
van WelyM, StossM, GorterRW. Toxicity of a standardized mistletoe extract in immunocompromised and healthy individuals. Am J Ther, 1999; 6:37–43.
81.
GorterRW, van WelyM, ReifM, StossM. Tolerability of an extract of European mistletoe among immunocompromised and healthy individuals. Altern Ther Health Med, 1999; 5:37–48.
82.
Memorial Sloan Kettering Cancer Center. Mistletoe (European). Online document at: www.mskcc.org/cancer-care/integrative-medicine/herbs/mistletoe-european Accessed October21, 2016.
83.
KaiserJD, DoneganE. Complementary therapies in HIV disease. Altern Ther Health Med, 1996; 2:42–52.
84.
PeltzerK, PreezNF, RamlaganS, FomundamH. Use of traditional complementary and alternative medicine for HIV patients in KwaZulu-Natal, South Africa. BMC Public Health, 2008; 24:25–5.
85.
Langlois-KlassenD, KippW, RubaaleT. Who's talking? Communication between health providers and HIV-infected adults related to herbal medicine for AIDS treatment in western Uganda. Soc Sci Med, 2008; 67:165–176.
86.
Bill and Melinda Gates Foundation. HIV: Strategy overview. Online document at: www.gatesfoundation.org/What-We-Do/Global-Health/HIV Accessed October21, 2016.
